PTK2 and prostate cancer: Similarly, Franzen et al. showed that apigenin reduces FAK/Src signaling in prostate cancer cells and that such effect was accompanied by actin cytoskeleton remodeling and by the appearance of exaggerated filopodia, which stimulated a strong attachment of cancer cells to an adhesive surface.